Altimmune CFO: 18,750 RSUs vested; 5,672 shares withheld

Altimmune (ALT) Form 4: Chief Financial Officer Gregory Weaver reported equity award activity on 11/11/2025.

Rhea-AI Filing Summary

Altimmune (ALT) Form 4: Chief Financial Officer Gregory Weaver reported equity award activity on 11/11/2025. 18,750 shares of Common Stock were acquired at $0 via the vesting and settlement of Restricted Stock Units (transaction code M). To cover taxes on vesting, 5,672 shares were surrendered at $4.28 (transaction code F). Following these transactions, he directly holds 23,078 shares of Common Stock.

The filing shows 56,250 RSUs remaining after the reported activity. Per the award terms, RSUs vest over four years, with 25% vesting on November 11, 2025 and the remainder in equal annual installments over the next three years, subject to continued service.

Insider Trade Summary

18,750 shares exercised/converted

Exercise 3 txns

Insider WEAVER GREGORY L

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	18,750	$0.00	$0.00
Exercise	Common Stock, par value $0.0001	18,750	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock, par value $0.0001	5,672	$4.28	$24K

Holdings After Transaction: Restricted Stock Units — 56,250 contracts (Direct); Common Stock, par value $0.0001 — 23,078 shares (Direct)

Footnotes (3)

1. F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
2. F2. Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
3. F3. The RSUs become vested over four (4) years with 25% of the shares vesting on November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Altimmune (ALT) disclose in this Form 4?

The CFO reported 18,750 shares acquired at $0 from RSU vesting and 5,672 shares surrendered at $4.28 for taxes on 11/11/2025.

How many ALT shares does the CFO hold after the transactions?

He directly holds 23,078 shares of Common Stock after the reported transactions.

What RSUs remain outstanding for the CFO at Altimmune (ALT)?

The filing shows 56,250 Restricted Stock Units outstanding following the reported activity.

What is the vesting schedule for the CFO’s RSUs at ALT?

RSUs vest over four years: 25% on November 11, 2025, then equal annual installments for three years, subject to continued service.

What were the transaction codes used in the Altimmune Form 4?

Code M for RSU settlement into shares and code F for shares withheld to cover taxes.

What price was used for the tax withholding on ALT shares?

The tax withholding transaction used a price of $4.28 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 04:07 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEAVER GREGORY L

(Last) (First) (Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG MD 20878

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001	11/11/2025		M		18,750	A	$0(1)	28,750	D
Common Stock, par value $0.0001	11/11/2025		F(2)		5,672	D	$4.28	23,078	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	11/11/2025		M			18,750	(3)	(3)	Common Stock, par value $0.0001	18,750	$0	56,250	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

2. Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.

3. The RSUs become vested over four (4) years with 25% of the shares vesting on November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

	/s/ Gregory Weaver	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.